LIVE WEBINAR
Share:

Aseptic Process Simulations: Designing and Evaluating Media Fills

  • Date
    17 September 2026
  • 11.00 AM Eastern Time (US/Canada)
    03.00 PM GMT

Course is now LIVE. Click below to join the session.

This course helps teams design and evaluate media fills that meaningfully challenge aseptic operations, address contamination risks, support operator qualification, and provide evidence that the process remains appropriately controlled. 

/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }
REGISTRATION OPTIONS

Live session Plus
Complimentary 30 Days Streaming access

$290  |  One participant (viewer)

$390  |  Team (2 - 5 participants)

$490 |  Team (6 - 10 participants)

REGISTER FOR THE COURSE

US $290 per learner

30-Days Unlimited Streaming Access

/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }

REGISTER FOR THE COURSE

To Get 30-Day Access to ONLY this Course 

US $290 per learner
  • This course is Included in Subscription Pack
Subscription include access to entire Learning Library
/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }
  • Faculty
    Danielle DeLucy
  • Duration
    60 Minutes
  • Course ID
    TF3599
  • Live Q&A +
    Post-live Continued Learning
  • Presentation Handout
    & Templates
  • Assessment
    & Certification Included

 

Why take this course?

Aseptic Process Simulations (APS), commonly called media fills, provide evidence that aseptic processing can be performed with minimal contamination risk when sterile drugs are filled into sterile containers. By replacing product with growth medium, the simulation challenges the process and the operators performing critical activities. Regulators use APS results to assess whether the aseptic process and personnel remain under appropriate control. 


Effective media fill design requires deliberate choices about interventions, worst-case conditions, execution frequency, participating operators, growth media, filling line speed, and evaluation of incubated units. This webinar addresses how these elements should be incorporated into an APS and how contamination risks should influence simulation design. Participants will also consider the use of media fills for operator qualification and the proper examination of units after incubation. The focus is on designing and evaluating periodic simulations that provide meaningful evidence of aseptic process control. 

Design APS Conditions That Meaningfully Challenge the Process 

Participants will develop a clearer basis for selecting interventions, worst-case conditions, operating speeds, growth media, and participating personnel when designing an APS. These choices determine whether the simulation meaningfully represents contamination risks within the aseptic process and provides useful evidence that process execution remains controlled. 

Strengthen Operator Qualification and Simulation Evaluation 

Media fills also provide evidence about the personnel executing aseptic activities. Participants will strengthen their ability to use APS for operator qualification, evaluate contamination risks, and examine incubated units correctly. These capabilities support periodic assessment of process control and the evidence regulators expect from organizations performing aseptic processing. 

Key Areas Covered

  • Current regulatory requirements for Aseptic Process Simulations 
  • Interventions and worst-case conditions in APS design 
  • Frequency and operator participation in media fills 
  • Growth media selection and filling line operating speeds 
  • Contamination risks within aseptic processing 
  • Operator qualification using Aseptic Process Simulations 
  • Incubation of media fill units 
  • Examination and evaluation of incubated units 

Who Must Attend

  • Lab Managers
  • Regulatory Departments
  • Quality Control Departments
  • Quality Assurance Departments
  • Manufacturing Departments
  • Operations Departments
  • Sterility Assurance Professionals
John E. Lincoln
COURSE DIRECTOR

Danielle DeLucy

Danielle DeLucy, has 25 years of pharmaceutical and biologics industry experience across Quality Management, Product Quality, Sterility Assurance, and QA oversight of filling and packaging operations. Her background as a Quality Control Pharmaceutical Microbiologist, combined with experience leading regulatory health inspections, directly supports the aseptic processing, contamination control, and media fill considerations addressed in this webinar. 

If you would like to request a Proforma invoice to sign up for this course. please click here

Commonly Asked Questions About This Subject

The following questions address practical regulatory, compliance, validation, quality, operational, and inspection-related considerations commonly associated with this subject.

How do you defend a media fill as truly representative of routine aseptic operations when production conditions vary from batch to batch? 

The strongest defense is a documented rationale showing that the simulation meaningfully challenged the contamination risks present during actual operations. Simply completing a successful media fill at the required frequency provides limited assurance if the conditions selected avoided activities that create the greatest aseptic risk. 


Inspection questions often focus on what happened during the run. Which interventions occurred? Were difficult manipulations actually performed? Did the simulation include operators, equipment states, line speeds, shift conditions, and operating durations that could meaningfully challenge aseptic control? 


A frequent weakness is designing a technically compliant simulation that becomes highly predictable. Operators know when interventions will occur, unusual conditions are minimized, and execution becomes cleaner than routine manufacturing. 


Historical production observations, intervention data, environmental monitoring trends, deviation history, and process knowledge provide stronger support for selecting simulation conditions. The documented rationale should make clear why the chosen conditions adequately represent the contamination opportunities the commercial process must control. 

What should happen when a media fill is successful but significant aseptic practice problems are observed during execution? 

A zero-growth result should not automatically close concerns identified during the simulation. If operators performed questionable interventions, disrupted first air, contacted critical surfaces, or departed from established aseptic technique, those observations require evaluation even when every incubated unit remains negative. 


This is an important inspection distinction. Absence of contamination in a finite number of units does not prove that an observed practice was acceptable. A contamination opportunity may have occurred without resulting in microbial transfer during that particular simulation. 


The event should be assessed according to what actually happened, its potential effect on aseptic conditions, and whether similar behavior could occur during commercial production. Depending on significance, the response may involve investigation, operator reassessment, procedural correction, additional simulation, or broader evaluation of production practices. 


A successful incubation result carries weight only when execution itself supports confidence in the aseptic process. Ignoring poor practices because the media remained sterile weakens that confidence considerably. 

How should an organization investigate a single contaminated media fill unit when no obvious contamination source can be identified? 

A single contaminated unit deserves a serious investigation because the purpose of the simulation is to challenge the ability of the process to prevent contamination. The absence of an immediately identifiable cause should increase attention to the event rather than encourage attribution to an unexplained laboratory or handling error. 


The investigation should reconstruct the unit's path through filling, interventions, equipment conditions, personnel activity, environmental information, incubation handling, and examination. Microbial identification can be particularly useful when compared with personnel and environmental monitoring isolates, although a matching organism does not by itself establish the contamination route. 


Inspection friction develops when investigations work backward from a preferred conclusion that the event was incidental. Unsupported statements such as "isolated occurrence" or "likely laboratory contamination" carry little weight without evidence. 


Where the source remains uncertain, the record should acknowledge that uncertainty and evaluate what it means for confidence in the aseptic process. An inconclusive investigation still requires a scientifically justified disposition and assessment of any further action. 

When should changes to an aseptic process trigger an additional media fill rather than waiting for the next scheduled simulation? 

An additional simulation should be considered when a change could alter contamination risk or the way aseptic operations are performed. The decision should come from a documented impact assessment rather than from the calendar for the next routine media fill. 


Changes involving equipment configuration, barrier systems, filling speeds, intervention methods, container formats, staffing patterns, processing duration, facility layout, or significant maintenance can alter conditions previously challenged during simulation. Even a change that has been technically qualified may introduce new operator interactions or contamination pathways. 


A weak change assessment simply states that the validated process remains unchanged. A stronger assessment identifies which aseptic risks were previously simulated, determines whether the change affects those conditions, and explains why existing evidence remains applicable or why additional simulation is necessary. 


This approach also prevents unnecessary media fills. The decision becomes defensible because it is connected to the actual contamination risk introduced by the change rather than an automatic requirement to repeat the exercise after every modification. 

Your TalkFDA Webinar Experience

When you reserve your seat, everything is organized for you — from access to certification from one place.

1. Confirmation

You receive a confirmation email and your course appears instantly in your TalkFDA dashboard.

2. Your Course Hub
Your TalkFDA course page becomes your central hub where you can join the session, access materials, and manage your learning.

3. Join the Live Training
At the scheduled time, click Join Session and you’ll be connected to the live Webex session with the instructor.

4. Watch Again Anytime
After the session, the playback becomes available on the same course page so you can revisit important sections.
5. Earn Your Certificate
Complete the course and your certificate is unlocked automatically in your learning history.

Everything related to your webinar: access, materials, playback, and certification — lives in one place.
Simple. Organized. Professional.
Go ahead and reserve your seat with confidence.

Built on 20+ years of global regulatory training experience across FDA, EMA, MHRA, and ICH frameworks.
Trusted by professionals across 80+ countries.

Testimonials

This is an upcoming session. Feedback below reflects experiences from similar programs delivered by our expert faculty.

“Session was easy to follow even for non-core team members. That helped.”
- Production Officer
“Good balance. Not too basic, not too deep. Worked well for mixed team.”
- Manager, Regulatory Affairs
“Team found it useful. Especially for aligning understanding across functions.”
- Director, Operations

Ready to Strengthen Your Team? Let’s Build Your Training Plan.

Whether you’re looking for a single onsite workshop or a multi-team training series, we’ll help you design a program that fits your goals, timelines, and operational reality.

Your team deserves the clarity.
Your organization deserves the confidence.

Upcoming Courses

Featured Courses